Background Interferon-gamma release assays (IGRAs) have been used to identify individuals at risk for developing active tuberculosis (TB). However, data regarding the risk of TB development in HIV-infected patients testing positive for IGRAs remain sparse in the era of combination antiretroviral therapy. Methods Between 2011 and 2013, 608 HIV-infected patients without active TB undergoing T-Spot. TB testing were enrolled in this prospective observational study at a university hospital designated for HIV care in Taiwan with a declining TB incidence from 72 per 100,000 population in 2005 to 53 per 100,000 population in 2012. All of the subjects were followed until September 30, 2014. The national TB registry was accessed to identify any TB cases among those lost to follow-up. Results T-Spot. TB tested negative in 534 patients (87.8%), positive in 64 patients (10.5%), and indeterminate in 10 patients (1.6%). In multivariate analysis, positive T-Spot. TB was significantly associated with older age (adjusted odds ratio [AOR], 1.172 per 10-year increase; 95% confidence interval [CI], 1.022-1.344, P=0.023), past history of TB (AOR, 13.412; 95% CI, 6.106-29.460, P<0.001), and higher CD4 counts at enrollment (AOR, per 50-cell/mu l increase, 1.062; 95% CI, 1.017-1.109, P=0.007). Of the 64 patients testing positive for T-Spot. TB, none received isoniazid preventive therapy and all but 5 received combination antiretroviral therapy at the end of follow-up with the latest CD4 count and plasma HIV RNA load being 592.8 cells/mu L and 1.85 log(10) copies/mL, respectively. One patient (1.6%) developed active TB after 167 person-years of follow-up (PYFU), resulting in an incidence rate of 0.599 per 100 PFYU. None of the 534 patients testing negative for T-Spot. TB developed TB after 1380 PYFU, nor did the 24 patients with old TB and positive T-Spot. TB tests develop TB after 62.33 PYFU. Conclusions The risk of developing active TB in HIV-infected patients with positive T-Spot. TB receiving combination antiretroviral therapy is low in Taiwan where the national TB program has led to a sustained decrease in TB incidence.
机构:
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul 138736, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul 138736, South Korea
Hong, Sun In
Lee, Yu-Mi
论文数: 0引用数: 0
h-index: 0
机构:
Inje Univ, Coll Med, Busan Paik Hosp, Dept Infect Dis, Pusan, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul 138736, South Korea
Lee, Yu-Mi
Park, Ki-Ho
论文数: 0引用数: 0
h-index: 0
机构:
Kyung Hee Univ, Sch Med, Kyung Hee Univ Hosp, Div Infect Dis,Dept Internal Med, Seoul, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul 138736, South Korea
Park, Ki-Ho
Kim, Sung-Han
论文数: 0引用数: 0
h-index: 0
机构:
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul 138736, South KoreaUniv Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul 138736, South Korea
机构:
Mae Sai Hosp, Mae Sai 57130, Chiang Rai, Thailand
Chiang Mai Univ, Fac Med, Clin Epidemiol Program, Chiang Mai 50000, ThailandMae Sai Hosp, Mae Sai 57130, Chiang Rai, Thailand
Nanta, Sirisak
Kantipong, Patcharee
论文数: 0引用数: 0
h-index: 0
机构:
Chiang Rai Reg Hosp, Chiang Rai, ThailandMae Sai Hosp, Mae Sai 57130, Chiang Rai, Thailand
Kantipong, Patcharee
Pathipvanich, Panita
论文数: 0引用数: 0
h-index: 0
机构:
Lampang Reg Hosp, Lampang, ThailandMae Sai Hosp, Mae Sai 57130, Chiang Rai, Thailand
Pathipvanich, Panita
Ruengorn, Chidchanok
论文数: 0引用数: 0
h-index: 0
机构:
Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Care, Chiang Mai 50000, ThailandMae Sai Hosp, Mae Sai 57130, Chiang Rai, Thailand
Ruengorn, Chidchanok
Tawichasri, Chamaiporn
论文数: 0引用数: 0
h-index: 0
机构:
Chiang Mai Univ, Fac Med, Clin Epidemiol Unit, Chiang Mai 50000, ThailandMae Sai Hosp, Mae Sai 57130, Chiang Rai, Thailand
Tawichasri, Chamaiporn
Patumanond, Jayanton
论文数: 0引用数: 0
h-index: 0
机构:
Chiang Mai Univ, Fac Med, Clin Epidemiol Unit, Chiang Mai 50000, ThailandMae Sai Hosp, Mae Sai 57130, Chiang Rai, Thailand